"3D Systems (DDD) is a leading provider of 3D printing centric design-to-manufacturing solutions including 3D printers, print materials and cloud sourced on-demand custom parts for professionals and consumers alike in materials including plastics, metals, ceramics and edibles. The company also provides integrated 3D scan-based design, freeform modeling and inspection tools. Its products and services replace and complement traditional methods and reduce the time and cost of designing new products by printing real parts directly from digital input. These solutions are used to rapidly design, create, communicate, prototype or produce real parts, empowering customers to manufacture the future."
You have bashed NKTR for many years. That is, you bashed the stock from when it was trading in the low teens. Aren't you embarrassed now that it is trading at around $14? Had we listened to your relentless bashing all of these years we would not be sitting on a ton of capital gains.
Do you continue your negative comments because you were fired by NKTR? Or do you do that because you unwisely shorted NKTR and now you have a tone of losses?
" Outstanding CEO (HR is the best in mid size biotech CEOs in the world!)"
I don't think so. NKTR PPS has been in the toilet for a long time because of the blunders of pre HR management as well as HR's management. Its shares should not have traded below $20 given its original technologies. HR made his shares of blunders and told us his shares of lies and misleading statements.
The market is finally realizing the value of NKTR technologies not because of what HR has done but because of passage of time allowing investors to understand the inherent value of NKTR technologies.
"we decided to close enrollment in this study after 80 patients were randomized due to challenges in recruiting new patients because the comparator arm of this study, single-agent irinotecan, is not the common standard of care for second line metastatic colorectal therapy in the U.S. or E.U."
Based on the above is it possible that the FDA may want a new study that compares 102 with the other common standard of care compounds? In other words is 102 being compared with an inferior compounds
(Irinotecan) that physicians no longer use rather than being compared with the best available compounds?
"I have had a change of heart I sold XONE did not like seeing this hit $55.00."
You never had any shares to sell shorty. You are a disguise short. Wwhom do you think you are going to con?
I tried to see if i could some of the secondary shares at the offering price from my brokerage firm. They said they had not been given any access to those shares. Apparently only favored customers of J.P. Morgan and Jefferies were able to get those shares.
Tried to search for it in google with no success. What is the title of the article? Are there any key words that could be used for search engines to find the article? I used several key words and nothing related to that came up.
You never posted on this board shorty. You have no NKTR shares to sell as you claim.
Why not be honorable and simply state that you are short this stock (and state your reason if you wish) rather than disguising as a long who is taking profit.
"HR 1 patient at 12 months and another 1 patient at 7 months shows us the 840 patient status"
What does that mean about the remaining 838 patients? Are they all dead?
I think for the United States, Canada, and many European countries the most efficacious HCV drug will be covered through insurance. However, if 135 combination is shown less efficacious, it is possible to market 135 as a cheaper option in the rest of the world as Third stated a while ago. The question that remains is assuming VRTX will be willing to sell a 12 week regimen of 135 combination at a low price, will GILD and others match VRTX's price. If so, then 135 may not really bring in much revenue.
I did pick NKTR last year and won the contest. I just did not want to win 2 years in a row. Not healthy for my ego. hehehe